Product Development - The company is focused on its lead product candidate, Niyad, which is being developed as a regional anticoagulant for continuous renal replacement therapy (CRRT) and has received Breakthrough Device Designation from the FDA[24][27]. - Niyad is currently undergoing a registrational trial with completion expected in 2026, and the study will evaluate 70 adult patients undergoing renal replacement therapy[26][28]. - The NEPHRO CRRT study has received IDE approval and is designed as a double-blinded trial to assess the efficacy of Niyad compared to placebo[28]. - Niyad's peak sales potential in the U.S. may exceed $200 million annually, targeting an addressable population of 500,000 patients undergoing CRRT and 350,000 patients undergoing IHD[32]. - Niyad would be the first FDA-approved regional anticoagulant for the extracorporeal circuit, currently dominated by heparin (43% usage) and citrate (28% usage)[35]. - Approximately 29% of current procedures do not use any anticoagulant, presenting a significant opportunity for Niyad[35]. - The annual estimate of DIC patients in the U.S. is over 250,000, which may be a targeted indication for the second nafamostat product candidate, LTX-608[33]. - The company is exploring LTX-608 for indications such as antiviral treatment and acute respiratory distress syndrome, with initial studies showing promising results in COVID patients[29]. Financial Performance - The company has incurred significant losses since inception and anticipates continued losses in the future, raising concerns about its ability to continue as a going concern[18][20]. - The acquisition of Lowell Therapeutics, Inc. was completed for approximately $32.5 million, with potential contingent consideration of up to $26.0 million based on regulatory and sales milestones[25]. - The estimated addressable market for CRRT is valued at $575 million, while the IHD market is valued at $3.5 billion[32]. Regulatory and Compliance - The FDA approval process for new drug applications is time-consuming and may involve unanticipated delays and costs, impacting the commercialization of product candidates[18][20]. - The approval process for Niyad involves substantial time and financial resources, with no certainty of timely approval from the FDA[52]. - Niyad, the lead product candidate, is classified as a Class III medical device and is undergoing the PMA application process, which typically takes between one and three years[63][66]. - The FDA has 180 days to review a filed PMA application, but the review often takes significantly longer due to potential requests for additional information[65]. - The Breakthrough Devices Program allows for expedited review of devices that provide significant advantages over existing treatments, although this designation does not guarantee FDA approval[69]. - Manufacturers must comply with stringent cGMP requirements throughout the manufacturing process, which includes testing each product batch prior to release[61]. - The Drug Supply Chain Security Act of 2013 mandates manufacturers to track and trace drug products, ensuring compliance with safety standards[72]. - The FDA may withdraw product approval if regulatory compliance is not maintained, which could lead to administrative actions such as fines or product recalls[62]. - Post-approval studies or market surveillance may be required to ensure ongoing safety and effectiveness of devices after market entry[68]. - The FDA conducts inspections of clinical trial data and manufacturing facilities prior to PMA approval, which can delay the approval process[66]. - Manufacturers are subject to federal and state healthcare laws that restrict certain business practices, including anti-kickback and false claims statutes[76][79]. - Compliance with data privacy regulations, such as HIPAA and GDPR, is essential to avoid significant penalties and ensure business transactions across borders[82]. Employee Relations - The company employed 12 full-time employees as of December 31, 2025, with a commitment to pay equity regardless of gender or race/ethnicity[97]. - The company conducts annual pay equity analyses to ensure fair compensation practices[97]. - Competitive salaries, wages, and benefits are offered to employees, along with stock options and restricted stock units under a broad-based stock incentive program[98]. - The company maintains a good relationship with its employees, none of whom are subject to a collective bargaining agreement[99]. Corporate Structure and Reporting - The company was originally incorporated as SuRx, Inc. in Delaware on July 13, 2005, and changed its name to Talphera, Inc. in January 2024[100]. - The company files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC[100]. - The company makes its SEC filings available on its website free of charge shortly after filing[100]. - The company is classified as a smaller reporting company and is not required to provide certain disclosures under the Exchange Act[304]. Supply Chain and Manufacturing - The company relies on third-party manufacturers and suppliers for its product candidates, which poses risks related to supply chain disruptions[20]. - The company relies on contract manufacturers for the production of Niyad and is in discussions for a backup manufacturer to ensure supply[40].

Financial Performance - HomesToLife reported a 13% year-on-year increase in net revenue to $377.9 million for FY2025, driven by a 12% rise in export revenue to $349.6 million[6]. - Net income surged 97% to $16.6 million in FY2025, translating to earnings per share of $0.185, with a return on average common shareholders' equity (ROE) of 86%[9]. - Gross profit increased by 27% to $105.3 million, with gross margin improving by 3.1 percentage points to 27.9% for FY2025[6]. - Revenue from retail doubled to $9.1 million, reflecting contributions from an expanded retail footprint in Korea[6]. - Total revenues for 2023 reached $325,984,469, with a slight increase projected to $335,060,851 in 2024 and $377,876,123 in 2025[23]. - Gross profit for 2023 was $86,246,393, with a decrease expected to $83,028,015 in 2024, followed by a significant increase to $105,304,801 in 2025[23]. - Net income for 2023 was $10,317,181, with a forecasted decrease to $8,420,771 in 2024, and an increase to $16,554,152 in 2025[23]. - Income from operations was $17,223,502 in 2023, with a decline to $9,511,652 in 2024, and a recovery to $19,371,359 in 2025[23]. Operating Expenses - Operating expenses rose 17% year-on-year to $86.0 million, primarily due to a $11.6 million increase in selling expenses[7]. - Operating expenses totaled $69,022,891 in 2023, with an increase to $73,516,363 in 2024 and further to $85,933,442 in 2025[23]. - Sales and distribution expenses were $51,622,790 in 2023, expected to rise to $54,727,281 in 2024 and $66,331,518 in 2025[23]. - General and administrative expenses were $17,400,101 in 2023, with a slight decrease to $17,348,952 in 2024 and an increase to $18,336,882 in 2025[23]. Cash Flow and Financing - Cash flow from operating activities increased significantly from $0.4 million in FY2024 to $13.5 million in FY2025[12]. - Total borrowings stood at $10.4 million as of December 31, 2025, primarily for short-term trade financing[13]. Future Projections - The company expects FY2026 revenue to range between $400 million to $420 million, reflecting continued growth driven by a robust export market[15]. Other Financial Metrics - The company recorded foreign exchange gains of $3.5 million in FY2025, compared to $2.2 million in FY2024[8]. - Cost of goods sold for 2023 was $239,738,076, projected to rise to $252,032,836 in 2024 and $272,571,322 in 2025[23]. - Income tax expense for 2023 was $1,864,201, with an increase to $2,415,742 in 2024 and $4,199,820 in 2025[23]. - Total other (expense) income, net for 2023 was $(5,042,120), with a recovery to $1,324,861 in 2024 and $1,382,613 in 2025[23]. Acquisitions - The company completed the acquisition of HTL Marketing in May 2025, enhancing its design and product development capabilities[19].

Revenue and Financial Performance - Revenue for the year ended December 31, 2025, was $3,363,538, an increase of $182,973 or 6% compared to $3,180,565 in 2024, primarily driven by increased orders for defense purposes [226]. - Gross profit for the year ended December 31, 2025, was $1,831,854, with a gross margin of 53%, down from 58% in 2024, attributed to increased cost of goods sold [230]. - The company incurred a net loss of $23.7 million for the year ended December 31, 2025, with accumulated losses of $54.1 million since inception [239]. Expenses - Sales and marketing expenses increased by $1,362,070 or 69% to $3,327,496 for the year ended December 31, 2025, primarily due to employee stock-based compensation [232]. - Research and development expenses rose by $2,769,621 or 130% to $4,897,030 for the year ended December 31, 2025, driven by costs related to employee stock-based compensation and development of new products [233]. - General and administrative expenses increased by $1,913,382 or 97% to $3,884,231 for the year ended December 31, 2025, mainly due to stock-based compensation and increased Nasdaq-related costs [234]. Cash Flow and Financing - Net cash used in operating activities decreased to $1,903,508 for the year ended December 31, 2025, from $3,206,549 in 2024, due to increased receipts from customers [245]. - Net cash provided by financing activities was $12,366,058 for the year ended December 31, 2025, compared to $3,475,156 in 2024, primarily from warrant exercises and share issuances [248]. - For the year ended December 31, 2024, net cash provided by financing activities was $3,475,156, a significant increase compared to net cash used of $271,616 in 2023 [249]. Financial Position - As of December 31, 2025, the company had cash and cash equivalents of $19.0 million and total receivables of $348,050, providing adequate financial resources for at least 12 months [241]. - As of December 31, 2025, material contractual obligations include operating lease obligations of $545,419 and net employee benefits of $234,133 [250]. Future Outlook and Risks - The company is closely monitoring macro-economic conditions, including inflation and supply chain issues, which may impact operations and cash flow [254]. - A 10% devaluation of the USD to NIS could increase net loss by approximately $296,000, while a 10% appreciation could decrease net loss by approximately $243,000 [405]. - The company does not currently hedge foreign currency exchange risk but may consider formal hedging transactions in the future [405]. - Existing funds are expected to cover operating expenses and capital expenditures for the next twelve months, despite liquidity risk due to operational expansion [407]. Capital Raising Activities - In February 2025, the company entered into a Sales Agreement to offer ordinary shares with an aggregate offering price of up to $37.0 million, with $10.0 million raised from the sale of 1,842,560 shares [252].

Financial Results - Bionano Genomics, Inc. reported preliminary financial results for Q4 and fiscal year ended December 31, 2025[4] - The report does not include specific financial figures or performance metrics in the provided content[5] - The financial results are not deemed "filed" under the Securities Exchange Act, limiting liability under that section[5] Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BNGO[2] - The company is classified as an emerging growth company under the Securities Act[3] - R. Erik Holmlin, Ph.D., serves as the President and CEO, acting as the principal executive and financial officer[10] Report Details - The press release detailing these results was issued on January 12, 2026[6] - The report includes an Inline XBRL exhibit for the cover page of the Current Report[6] - The report does not provide details on user data, future outlook, or new product developments[5] - No information on market expansion or mergers and acquisitions is included in the content[5]

Financial Performance - FY 2025 revenue reached $186.5 million, reflecting a 24.7% increase year-over-year, with organic revenue growth of 6.2%[6] - Adjusted EBITDA for FY 2025 was $45.4 million, up 17.7% from the previous year, achieving a margin of 24.3%[6] - Adjusted Net Income for FY 2025 was $36.6 million, representing a 32.1% increase compared to FY 2024[7] - Total revenue for the year ended December 31, 2025, was $186.5 million, a 24.7% increase from $149.6 million in 2024[37] - Adjusted EBITDA for the year ended December 31, 2025, was $45.4 million, up 17.7% from $38.6 million in 2024, with a margin of 24.3%[36] - Adjusted EPS for 2025 was $1.48, reflecting a 26.4% increase from $1.17 in 2024[64] - The net loss for 2025 was $39,001,000, compared to a net loss of $23,957,000 in 2024, representing a 62.9% increase in losses[88] Quarterly Performance - Q4 2025 revenue increased by 27.8% to $49.9 million, with organic growth contributing 5.4%[7] - Total revenue for Q4 2025 increased by 27.8% to $49.9 million compared to $39.0 million in Q4 2024[31] - Adjusted Net Income for Q4 2025 was $11.3 million, a 66.1% increase from $6.8 million in Q4 2024[29] - Adjusted EBITDA for Q4 2025 reached $12.4 million, up 27.1% from $9.8 million in Q4 2024[28] - Adjusted EPS (basic) for Q4 2025 was $0.45, a 58.5% increase from $0.28 in Q4 2024[28] Client Growth and Retention - The client base grew to approximately 1,400, with 613 clients spending over $100,000, an increase from 503 in 2024[14][25] - The Group's revenue retention rate stands at approximately 86%, demonstrating strong client relationships[24] Acquisitions and Strategic Initiatives - The company completed two acquisitions in 2025, enhancing its capabilities and geographic reach[6] - PPHC expects average organic revenue growth of approximately 5% in 2026, supplemented by acquisitions[17] - The company aims to retain more cash flow for M&A activities and long-term growth, leading to a proposed reduction in dividends[63] Tax and Financial Costs - The effective tax rate improved to (2.4)% in Q4 2025 from 19.6% in Q4 2024, a change of 21.9 percentage points[28] - The effective tax rate improved to 10.7% in 2025 from 19.1% in 2024, driven by structural differences in tax accounting[43] - The Group's net finance costs rose to $3.3 million in 2025 from $1.7 million in 2024, reflecting additional debt from acquisitions[42] Cash Flow and Liquidity - Adjusted Free Cash Flow for the year ended December 31, 2025, was $36.9 million, a 66.1% increase from $22.2 million in 2024[47] - Cash and cash equivalents at the end of 2025 were $20.4 million, a 40.6% increase from $14.5 million in 2024[54] - Cash and cash equivalents increased to $20,436,000 in 2025, up from $14,536,000 in 2024, a growth of 40.3%[86] - Net cash provided by operating activities increased to $24,770 in 2025 from $16,403 in 2024, reflecting improved operational efficiency[94] Debt and Equity - Net Debt position rose to $26.6 million as of December 31, 2025, compared to $17.5 million in 2024, primarily due to the acquisition of TrailRunner[53] - Total Debt increased to $47.0 million in 2025, up 46.6% from $32.0 million in 2024[54] - The number of shares outstanding increased by 23.3% to 20,822 thousand shares by the end of 2025[64] - The number of shares outstanding increased to 25,174,492 in 2025 from 24,017,599 in 2024, reflecting a growth of 4.8%[90] Operational Expenses - Operating expenses totaled $220,454,000 in 2025, up from $167,716,000 in 2024, reflecting a 31.4% increase[88] - The company incurred $5,676,000 in depreciation and amortization expenses in 2025, compared to $4,244,000 in 2024, a rise of 33.9%[88] Dividend Policy - Dividend payments decreased from $16.8 million in 2024 to $8.7 million in 2025, reflecting a new dividend policy[50] - The company declared a total dividend of $0.355 per Common Stock for 2025, amounting to approximately $9.7 million[62] - Dividends paid decreased significantly to $8,656 in 2025 from $16,836 in 2024, reflecting a strategic decision to conserve cash[94]

Financial Performance - Revenues for the Battery & Energy Products segment for the year ended December 31, 2025, were $178,042, with a segment contribution of $20,223, compared to revenues of $144,081 and a segment contribution of $18,997 for the year ended December 31, 2024[23]. - Revenues for the Communications Systems segment for the year ended December 31, 2025, were $13,117, with a segment contribution of $(1,290), compared to revenues of $20,375 and a segment contribution of $1,191 for the year ended December 31, 2024[26]. - Consolidated revenues increased by $26,703 or 16.2% to $191,159 for the year ended December 31, 2025, compared to $164,456 for 2024[201]. - Battery & Energy Products revenues increased by $33,961 or 23.6% to $178,042, with core organic growth contributing $7,424 or 5.4%[213]. - Net loss attributable to Ultralife Corporation was ($5,898), or ($0.35) per share, compared to a net income of $6,312, or $0.38 per share for 2024[208]. - Adjusted EBITDA for 2025 amounted to $17,284, compared to $16,480 for the prior year[209]. - The effective tax rate increased to 29.1% for 2025, up from 22.8% in 2024, primarily due to the geographic mix in earnings[206]. Corporate Strategy and Initiatives - Ultralife's strategic rebranding initiative aims to consolidate all sub-brands under a unified master brand, which is expected to enhance operational efficiency and customer recognition[17]. - The company continues to seek development contracts with public and private customers, resulting in intellectual property that may enhance commercialization of new products[22]. - Ultralife's acquisition of Excell Battery Group has allowed for diversification of commercial revenue and expansion into new end markets, enhancing the Battery & Energy Products business[38]. - On October 31, 2024, the company acquired Electrochem Solutions, Inc., enhancing its operating leverage and creating opportunities for gross margin expansion through manufacturing cost efficiencies and vertical integration[39]. - The acquisition of Electrochem is expected to drive revenue growth through cross-selling activities and extend the company's reach into underserved adjacent markets[39]. - The company has made several acquisitions to diversify revenue and expand market reach, including Accutronics in 2016, Southwest Electronic Energy Corporation in 2019, and Excell Battery Canada Inc. in 2021[196][197][198]. Market and Customer Insights - A significant portion of the company's revenue, 27% in 2025 and 23% in 2024, came from L3Harris Technologies, indicating reliance on a major customer[62]. - The company reported sales to U.S. customers of $137,077 and to foreign customers of $54,082 in 2025, compared to $97,040 and $67,416 in 2024, respectively[62]. - Sales to non-U.S. customers accounted for 28% of total revenues in 2025 and 41% in 2024, indicating a significant reliance on international markets[157]. - Sales to U.S. and foreign militaries accounted for 34% of revenues in 2025, down from 38% in 2024, totaling $65,864 and $62,374 respectively[115]. - Approximately $58,647 or 31% of net revenue in 2025 came from U.S. Government customers, compared to $54,077 or 33% in 2024[116]. Research and Development - Research and development expenditures increased to $12,079 million in 2025 from $9,549 million in 2024, reflecting a year-over-year growth of 26%[84]. - The company expects research and development expenditures to increase by 10% or more over 2025 levels in 2026 due to ongoing initiatives[85]. - The company is focused on developing new battery and power solutions, with significant resources allocated to research and development across multiple global facilities[84]. Operational Challenges - The company has experienced interruptions in product deliveries from sole source suppliers in 2024 and 2025, which may affect future shipments and financial performance[77]. - The company has experienced supply chain disruptions and rising costs due to tariffs and inflation, which have affected its business operations[112]. - The company experienced production and shipping downtime for several weeks due to a cybersecurity incident, resulting in lost sales orders[132]. - The company is subject to fluctuations in oil and gas prices, which could materially affect its financial condition and results of operations[134]. - The company faces unique risks in its operations in China, including political changes and trade restrictions, which could adversely impact its business[135]. - The company is exposed to safety risks associated with lithium batteries, which could lead to significant production delays or claims for damages[138]. Compliance and Regulatory Issues - The company is subject to compliance with ITAR and EAR regulations, with future estimated costs associated with compliance not deemed significant at present[102]. - The company is required to comply with the EU RoHS Directive, which restricts the use of certain hazardous substances in electrical and electronic equipment, and the compliance costs are currently estimated to be not significant[166]. - The company is subject to various environmental regulations, which could impose costly compliance requirements and affect operating income and margins[165]. - The company emphasizes compliance with procurement laws and anti-corruption regulations to mitigate legal risks[172][173]. Inventory and Backlog - Backlog orders for Battery & Energy Products were approximately $102,000 and $95,000 as of December 31, 2025, and 2024, respectively, reflecting continued high demand[67]. - As of December 31, 2025, the backlog orders for Communications Systems were approximately $8,200 million, up from $7,600 million in 2024, indicating a year-over-year increase of 7.9%[69]. - The total carrying value of Battery & Energy Products inventory increased by 2% year-over-year, amounting to $45,322 million in 2025 compared to $44,614 million in 2024[80]. - The total carrying value of Communications Systems inventory rose by 29% year-over-year, reaching $8,686 million in 2025 from $6,749 million in 2024[83]. - The total carrying value of the company's inventory reflects strategic procurement to fulfill backlog orders, particularly in the government and defense sectors[80]. Employee and Organizational Structure - The company employed a total of 678 employees as of December 31, 2025, with 525 in production, 92 in sales and administration, and 61 in research and development[109]. - The company believes its facilities are adequate for current needs, with operations in multiple locations including Newark, New York, and Shenzhen, China[183]. Financial Position and Debt - The company has a $55 million senior secured term loan and a $30 million revolving credit facility, with $50.25 million outstanding on the term loan as of December 31, 2025[144]. - Interest and financing expenses increased by $2,013, or 103.8%, due to the financing of the Electrochem acquisition[205]. - The company had approximately $8,800 million of federal net operating loss carryforwards, $5,100 million of state net operating loss carryforwards, and $3,400 million of federal general business tax credit carryforwards available to offset future taxable income as of December 31, 2025[158]. Competitive Landscape - The company faces intense competition in both battery and communications systems markets, with many competitors having greater resources[107]. - The company is focused on developing new products and commercial applications, but market acceptance remains uncertain due to competitive pressures[119]. - Negative publicity regarding Lithium-ion batteries could reduce demand for the company's products and adversely affect its business[154].

Financial Performance - Cato Corporation reported a net loss of $10.7 million or $0.55 per diluted share for Q4 2025, an improvement from a net loss of $14.1 million or $0.74 per diluted share in Q4 2024 [2]. - Sales for Q4 2025 were $150.0 million, a decrease of 3.4% from $155.3 million in Q4 2024; however, full-year sales increased by 0.7% to $646.8 million from $642.1 million in 2024 [3]. - Income tax benefit for Q4 2025 was $1.1 million compared to an expense of $0.3 million in the previous year [4]. Gross Margin and Expenses - Gross margin for Q4 2025 improved to 29.2% of sales, up from 28.0% in Q4 2024, primarily due to lower payroll and occupancy costs [4]. - For the full year 2025, gross margin increased to 33.3% from 32.0% in 2024, attributed to lower payroll, distribution, and freight costs [5]. - SG&A expenses as a percentage of sales decreased from 36.0% in 2024 to 35.0% in 2025, reflecting cost control measures [5]. Store Operations - The company closed 48 stores during 2025, operating 1,069 stores as of January 31, 2026, down from 1,117 stores a year earlier; plans to open up to 10 new stores and close up to 40 underperforming stores in 2026 [7]. - Year-to-date same-store sales increased by 4% compared to 2024, indicating a positive trend despite previous supply chain disruptions [3]. Future Outlook - The company anticipates challenges in 2026 due to economic uncertainties and pressure on customers' disposable income [6]. - Total current assets decreased to $193.3 million as of November 1, 2025, from $223.2 million as of February 1, 2025 [12].

Revenue Sources and Market Focus - Ambarella's revenue primarily comes from human-viewing applications, including IP security cameras and drones, with a focus on AI-driven perception and autonomous business development [19]. - Sales to customers in Asia accounted for approximately 88%, 85%, and 79% of total revenue in the fiscal years ended January 31, 2026, 2025, and 2024, respectively, indicating a strong reliance on the Asian market [59]. - In fiscal year 2026, WT Microelectronics Co., Ltd. accounted for approximately 70% of total revenue, highlighting reliance on a limited number of customers for significant revenue [62]. - Revenue from the top 10 end customers accounted for approximately 67% of total revenue in fiscal year 2026, highlighting dependency on a limited customer base [118]. - Approximately 70%, 63%, and 53% of the company's revenue was derived from sales through the distributor WT for the fiscal years ended January 31, 2026, 2025, and 2024 respectively [161]. - The company anticipates that a significant portion of its revenue will continue to be derived from sales through WT in the foreseeable future, with the current agreement effective until January 2029 [161]. Product Development and Technology - The latest CVflow architecture enables advanced AI inference capabilities, processing transformer AI networks for applications like object detection and semantic segmentation [20]. - The CV7, CV3, and N1 product families utilize 4 and 5 nanometer process technology, enhancing performance for edge AI applications in automotive and robotics [21]. - The N1 SoC supports LLM inferencing with models up to 34 billion parameters, facilitating generative AI applications on IoT devices [23]. - Ambarella's adaptive AI radar software improves radar perception, achieving higher resolution and accuracy while reducing power consumption compared to traditional systems [24]. - The edge AI inference market requires a different SoC architecture than traditional data center approaches, focusing on real-time perception and minimal latency [27]. - The company leads in the security camera market, offering AI products that enhance automation through advanced algorithms like facial recognition and object tracking [31]. - The CVflow architecture allows customers to differentiate their products by porting their own or third-party neural networks and AI algorithms, creating a flexible platform for innovation [36]. - The advanced VLSI design expertise enables the company to build SoCs on 4 nm and 5 nm process technology, with the first SoC design on a 2 nm process node recently taped out [37]. - The Cooper Development Platform simplifies the integration of software, hardware, and AI models, supporting the entire portfolio of AI SoCs [57]. - The developer zone provides optimized AI models and low-code/no-code blueprints to accelerate the development of edge AI applications, enhancing the ecosystem for partners [36]. Research and Development - Approximately 75% of employees are engaged in research and development, indicating a strong focus on innovation and product development [72][89]. - Research and development expenses were approximately $238.5 million, $226.1 million, and $215.1 million for fiscal years 2026, 2025, and 2024, respectively, with expectations for increased investment in innovative AI inference SoCs [131]. Market Challenges and Risks - The global semiconductor market is highly competitive, with increasing pressure from larger companies and new entrants, which may affect pricing and profitability [74][76]. - The company faces risks from global macroeconomic conditions, including high inflation and geopolitical tensions, which may adversely impact business and financial condition [94]. - Supply chain challenges, including shortages and increased costs of wafers and materials, could adversely affect gross margins and revenues [95]. - The semiconductor industry has experienced significant shortages, leading to increased manufacturing lead times and potential revenue harm [105]. - The company faces risks related to supply shortages or delays from third-party component suppliers, which could delay customer orders [106]. - The semiconductor industry is cyclical, and the company expects these cyclical conditions to continue, making quarterly operating results difficult to predict [146]. - The company faces challenges in managing growth effectively, particularly with an executive team in the U.S. and the majority of employees in Asia, which could impact business execution [134]. - The company relies on a limited number of customers for a significant portion of revenue, making it vulnerable to customer retention issues [95]. - The complexity of managing manufacturing capacity and supply chain may lead to increased costs and reduced gross margins due to external factors [104]. Compliance and Regulatory Risks - The company is subject to warranty and product liability claims, which may require significant expenditures to defend or pay damage awards, potentially harming its financial condition [180]. - The company is subject to governmental export and import controls that could impair its ability to compete in international markets and affect revenue [176]. - The legislative framework for data processing and privacy is rapidly evolving, with potential fines of up to €20 million or 4% of annual global revenues for noncompliance with GDPR [181]. - Compliance with Section 404 of the Sarbanes-Oxley Act is costly and any material weakness in internal controls could harm market confidence and stock price [189]. - The evolving regulatory landscape may require modifications to products and incur substantial costs to ensure compliance [183]. Employee and Operational Insights - As of January 31, 2026, the company employed 959 people, with a diverse workforce and a commitment to employee relations and training [89]. - Approximately 92% of eligible U.S. employees participate in the 401(k) plan, and 88% participated in the employee stock purchase plan [90]. - The average tenure of employees is approximately 8.1 years, with about 31% having been employed for more than 10 years [91]. - The worldwide voluntary employee turnover rate in fiscal year 2026 was approximately 7.7% [91]. Financial and Market Performance - The company has approximately $121.6 million invested in marketable debt securities as of January 31, 2026 [153]. - The market price of the company's ordinary shares has historically been volatile, influenced by various external factors, which may affect investment returns [207]. - Future revenue and operating profit projections are subject to fluctuations, including economic conditions and market performance of comparable companies [208]. Intellectual Property and Legal Risks - The semiconductor industry faces significant risks related to intellectual property rights, with potential litigation costs and liabilities [201]. - The company may need to initiate litigation to protect intellectual property rights, which can be expensive and time-consuming [199]. - Open source software usage may expose the company to risks that could compromise proprietary technology and require disclosure of source code [204].

Financial Reporting and Performance - Eni's consolidated financial statements are prepared in accordance with International Financial Standards (IFRS) as issued by the IASB[19]. - The company emphasizes the importance of forward-looking statements regarding future events and results, which are subject to risks and uncertainties[25]. - Eni's net borrowings are calculated as total finance debt less cash, cash equivalents, and certain very liquid investments, providing a measure of financial condition[31]. - The Total Shareholder Return (TSR) is assessed on a yearly basis, accounting for changes in market price and dividends distributed[32]. - Eni's market share estimates are based on management's assessments and independent market studies[27]. - The Group's financial performance is significantly affected by hydrocarbon price volatility, with lower prices leading to reduced revenues and cash flow, particularly in the Exploration & Production segment[54]. - Eni does not hedge its future expected cash flows from the sale of proved reserves, increasing exposure to commodity risk[54]. - The net present value of Eni's proved reserves was approximately €42.9 billion at December 31, 2025, a decrease of €12.6 billion from the previous year[128]. - Eni's operations are subject to high levels of income taxes and royalties, which may increase with rising oil prices, impacting net profits[124]. - Eni's compliance expenses may increase due to the adoption of carbon pricing mechanisms, with about half of its direct GHG emissions currently included in such schemes[82]. - Materialization of these risks could adversely affect Eni's financial condition, business prospects, and shareholder returns, including dividends and stock repurchases[169]. Production and Reserves - Eni's average reserve life index is calculated as the ratio between the amount of reserves at year-end and total production for the year[33]. - The Group's reported production and reserves increased by approximately 4 KBOE/d and 12 mmBOE, respectively, due to a decreased Brent reference price in 2025[55]. - Eni's production is estimated to vary by up to 1 KBOE/d for each one-dollar change in the price of Brent crude oil, highlighting the sensitivity of operations to commodity price fluctuations[55]. - Eni's future production levels are highly dependent on the success of exploration projects, with unsuccessful activities potentially leading to reduced oil and gas production[108]. - Approximately €45.3 billion in future development and decommissioning costs are associated with Eni's proved total reserves, indicating substantial financial commitments[121]. - As of December 31, 2025, about 44% of Eni's total estimated proved reserves by volume were undeveloped, requiring significant capital expenditures and successful drilling operations[121]. - Eni's ability to replace produced reserves is critical for future production and growth, with potential downward revisions in reserves impacting business prospects[116]. - Eni's production in Libya was 155 kboe/d in 2025, accounting for approximately 10% of the Group's total production[134]. Market and Economic Conditions - Crude oil prices have declined to a range of $60-70/bbl for the rest of the year, closing at a yearly average price of $69/bbl, down 14.5% year-on-year[50]. - The Brent crude oil price is estimated at $70/bbl in nominal terms for 2026, based on moderate global economic growth assumptions[50]. - Natural gas prices in Europe averaged in line with 2024, reflecting seasonal consumption rather than improving fundamentals[51]. - The price of natural gas in the United States was one fifth that of Europe in 2025, highlighting regional supply dynamics[51]. - OPEC+ decisions on production levels significantly influence short-term crude oil prices, with a recent resolution to unwind production cuts impacting supply[48]. - Global economic growth has slowed, influenced by trade disputes and high interest rates, affecting crude oil demand[50]. - The development of liquefaction capacity in the US, Qatar, and Australia has created a global liquid market for natural gas, increasing price volatility[51]. - Geopolitical tensions, particularly in the Middle East, have negatively affected investor confidence and economic activity, impacting oil prices[50]. Environmental and Regulatory Risks - Eni's GHG emissions are reported in CO2 equivalent, reflecting its commitment to environmental sustainability[34]. - Eni's management acknowledges that the transition to a low-carbon economy poses risks to long-term demand for hydrocarbons[49]. - Rising climate change concerns and regulatory pressures may lead to a decline in demand for hydrocarbons, potentially affecting prices and financial performance[78]. - Eni aims to increase the proportion of natural gas in its production mix while gradually reducing hydrocarbons in its portfolio, targeting net zero emissions of CO2 by 2050[79]. - In 2025, Eni accrued an expense of approximately €800 million for carbon allowances corresponding to 11.3 million tons of CO2 emissions, with a projected total expense of €850 million for 2024[82]. - Eni's operations are subject to regulatory risks, including potential stricter regulations on carbon emissions that could increase compliance costs and operational constraints[81]. - The company is expanding its portfolio of low or zero carbon products, including renewable electricity and biofuels, but faces challenges in achieving expected returns due to competition and regulatory uncertainties[99][101]. - Climate-related risks, including extreme weather events, could materially disrupt Eni's operations and negatively affect its financial condition and shareholder returns[98]. - Legal risks from climate-based litigation could result in significant financial liabilities for Eni, affecting its operations and business prospects[88][90]. Operational and Strategic Risks - The company is focused on enhancing recovery techniques to increase production from existing wells[33]. - Eni is actively involved in the development of new technologies to improve the commercial viability of its resources[33]. - The company anticipates that rising costs of capital and reduced access to financing may hinder its ability to invest in future oil and gas projects[95]. - Eni plans to invest approximately €29 billion in capital expenditures for the 2026-2030 period to explore and develop hydrocarbon reserves[123]. - The company faces significant operational risks in development projects, including potential cost overruns and delays due to complex activities and external factors[109]. - Eni is exposed to political risks, with 84% of its proved hydrocarbon reserves located in non-OECD countries, which may affect operational stability[129]. - The company is not fully insured against all potential HSE risks, which could lead to substantial liabilities in the event of a major environmental disaster[152]. - Eni has invested heavily in upgrading safety and reliability measures, but risks remain that could adversely affect operations and financial results[153]. - The Group faces potential environmental liabilities from past operations, with ongoing remediation efforts at several industrial sites in Italy[155]. - Eni is involved in various legal proceedings that could result in significant financial losses due to environmental claims and compliance issues[158]. - The Company is actively seeking acquisition opportunities to achieve growth targets, but such acquisitions carry integration and financial risks[159]. - Eni's crisis management systems may be ineffective, potentially prolonging disruptions and adversely impacting financial results[160]. Financial and Credit Risks - Eni is exposed to credit risk, which may lead to loss provisions and cash flow shortfalls if counterparties default or fail to meet obligations[167]. - Liquidity risk could hinder Eni's ability to secure funding or sell assets, negatively impacting operations and cash flows[168]. - In 2025, the Euro appreciated by 4.4% against the U.S. dollar, negatively impacting reported results by an estimated €0.5 billion[166]. - The Group is exposed to treasury and trading risks, including commodity price volatility, which could lead to substantial losses[165]. - The ongoing geopolitical tensions and macroeconomic risks could negatively impact global demand for hydrocarbons, affecting Eni's results of operations[63].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-40133 ENVOY MEDICAL, INC. (Exact name of registrant as specified in its charter) | Delaware | 86-1369123 | | --- | --- ...